Record Information |
---|
Version | 4.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:52 UTC |
---|
Update Date | 2020-02-26 21:41:58 UTC |
---|
HMDB ID | HMDB0015632 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Temsirolimus |
---|
Description | Temsirolimus, also known as CCI 779 or torisel, belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring. Temsirolimus is a drug which is used for the treatment of renal cell carcinoma (rcc). also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma. Temsirolimus is an extremely weak basic (essentially neutral) compound (based on its pKa). Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). In in vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTOR and resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and the vascular endothelial growth factor. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007. Primarily metabolized by cytochrome P450 3A4 in the human liver. Temsirolimus has been administered to patients with cancer in phase 1 and 2 trials with repeated intravenous doses as high as 220 mg/m2. Inhibition of mTOR activity resulted in a G1 growth arrest in treated tumor cells. Other metabolic pathways observed in in vitro temsirolimus metabolism studies include hydroxylation, reduction and demethylation. Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). |
---|
Structure | |
---|
Synonyms | Value | Source |
---|
CCI 779 | Kegg | 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin | Kegg | Torisel | Kegg | 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoic acid]rapamycin | Generator | CCI-779 | HMDB | Wyeth brand OF temsirolimus | HMDB | Rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate) | MeSH |
|
---|
Chemical Formula | C56H87NO16 |
---|
Average Molecular Weight | 1030.2871 |
---|
Monoisotopic Molecular Weight | 1029.602485741 |
---|
IUPAC Name | (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate |
---|
Traditional Name | temsirolimus |
---|
CAS Registry Number | 162635-04-3 |
---|
SMILES | OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC |
---|
InChI Identifier | InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1 |
---|
InChI Key | CBPNZQVSJQDFBE-FUXHJELOSA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Benzenesulfonamides |
---|
Direct Parent | Benzenesulfonamides |
---|
Alternative Parents | |
---|
Substituents | - Benzenesulfonamide
- Benzenesulfonyl group
- Pyrazolopyrimidine
- Phenoxy compound
- Phenol ether
- Alkyl aryl ether
- Pyrimidone
- Organosulfonic acid amide
- N-alkylpyrrolidine
- Pyrimidine
- Azole
- Pyrrolidine
- Vinylogous amide
- Heteroaromatic compound
- Aminosulfonyl compound
- Sulfonyl
- Pyrazole
- Organosulfonic acid or derivatives
- Organic sulfonic acid or derivatives
- Tertiary aliphatic amine
- Tertiary amine
- Ether
- Azacycle
- Organoheterocyclic compound
- Organic oxide
- Organosulfur compound
- Organooxygen compound
- Organonitrogen compound
- Organic nitrogen compound
- Organopnictogen compound
- Organic oxygen compound
- Hydrocarbon derivative
- Amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
|
Disposition | Biological location: |
---|
Role | Industrial application: |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.0024 g/L | Not Available | LogP | Not Available | Not Available |
|
---|
Predicted Properties | |
---|
General References | - Boni J, Leister C, Burns J, Cincotta M, Hug B, Moore L: Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. J Clin Pharmacol. 2007 Nov;47(11):1430-9. Epub 2007 Oct 3. [PubMed:17913896 ]
- Mounier N, Vignot S, Spano JP: [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor]. Bull Cancer. 2006 Nov;93(11):1139-43. [PubMed:17145584 ]
- Shuuin T, Karashima H: [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma]. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9. [PubMed:19620795 ]
- (). Wyeth Pharmaceuticals Inc. Torisel® (temsirolimus) injection prescribing information. Philadelphia, PA: 2010 Sep.. .
|
---|